- Home
- CNK vs ARQT Comparison
CNK vs ARQT Comparison
Compare CNK & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNK | ARQT |
|---|---|---|
| Founded | 1984 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.3B |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CNK | ARQT |
|---|---|---|
| Price | $24.29 | $26.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | ★ $33.45 | $24.83 |
| AVG Volume (30 Days) | ★ 2.8M | 1.5M |
| Earning Date | 02-18-2026 | 02-25-2026 |
| Dividend Yield | ★ 1.49% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.11 | N/A |
| Revenue | ★ $3,153,000,000.00 | $317,929,000.00 |
| Revenue This Year | $5.95 | $85.83 |
| Revenue Next Year | $7.68 | $30.72 |
| P/E Ratio | $21.67 | ★ N/A |
| Revenue Growth | 9.70 | ★ 129.21 |
| 52 Week Low | $21.60 | $11.13 |
| 52 Week High | $34.01 | $31.77 |
Technical Indicators
Market Signals| Indicator | CNK | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 52.28 | 42.42 |
| Support Level | $23.57 | $25.12 |
| Resistance Level | $24.81 | $27.08 |
| Average True Range (ATR) | 1.03 | 1.39 |
| MACD | 0.25 | -0.23 |
| Stochastic Oscillator | 64.72 | 24.33 |
Price Performance
Historical ComparisonAbout CNK Cinemark Holdings Inc Cinemark Holdings Inc.
Cinemark Holdings Inc is a geographically diverse operator in the motion picture exhibition industry in the United States. The company generates revenue from filmed entertainment box office receipts and concession sales, with additional revenue from screen advertising, screen rentals, and other revenue streams, such as transactional fees, vendor marketing promotions, studio trailer placements, meeting rentals, and electronic video games located in some of the theatres.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.